A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

New York University Langone Health, New York

Memorial Sloan Kettering Cancer Center, New York

Gettysburg Cancer Center, Gettysburg

Piedmont Hospital, Atlanta

Northside Hospital, Atlanta

Florida Cancer Specialists, Tallahassee

Florida Cancer Specialists, West Palm Beach

Florida Cancer Specialists, Fort Myers

Sarah Cannon Research Institute, Nashville

Ohio State University, Columbus

Cleveland Clinic, Cleveland

Indiana University Cancer Center, Indianapolis

University of Michigan, Ann Arbor

Henry Ford Hospital, Detroit

Wisconsin Carbone Cancer Center, Madison

University of Minnesota Cancer Center, Minneapolis

Northwestern University Medical Center, Chicago

University of Chicago, Chicago

University of Kansas, Fairway

Nebraska Methodist Hospital, Omaha

Mary Crowley Research Center, Dallas

University of Texas, Houston

University of Colorado, Aurora

Arizona Oncology, Tucson

Comprehensive Cancer Centers of Nevada, Las Vegas

University of California - San Francisco, San Francisco

Seattle Cancer Care Alliance, Seattle

Dana-Farber Cancer Institute, Boston

Rutgers Cancer Institute, New Brunswick

Site CA15003, Ottawa

Site JP81004, Nagoya

Site JP81001, Kashiwa

Site JP81005, Chuo-ku

Site JP81007, Ōsaka-sayama

Site JP81011, Kitaadachi-Gun

Site JP81006, Nakatogari

Site JP81003, Chūō

Site JP81002, Koto

Site JP81010, Okayama